Do analysts prefer LGVN or GNPX?

Longeveron currently has a consensus price target of $80.00, indicating a potential upside of 3,178.69%. Given Longeveron's stronger consensus rating and higher probable upside, analysts plainly believe Longeveron is more favorable than Genprex. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Longeveron 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Genprex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is LGVN or GNPX more profitable?

Genprex has a net margin of 0.00% compared to Longeveron's net margin of -1,977.59%. Genprex's return on equity of -163.12% beat Longeveron's return on equity. Company Net Margins Return on Equity Return on Assets Longeveron -1,977.59% -223.19% -150.20% Genprex N/A -163.12% -128.98%

Do analysts rate GNPX or OSRH?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Genprex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 OSR 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings & valuation, GNPX or OSRH?

Genprex has higher earnings, but lower revenue than OSR. OSR is trading at a lower price-to-earnings ratio than Genprex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Genprex N/A N/A -$16.23M -$133.36 N/A OSR $1.81M 4.17 -$27.06M -$0.37 N/A

Is GNPX or OSRH more profitable?

Genprex has a net margin of 0.00% compared to OSR's net margin of -593.15%. OSR's return on equity of -8.36% beat Genprex's return on equity. Company Net Margins Return on Equity Return on Assets Genprex N/A -163.12% -128.98% OSR -593.15% -8.36% -6.24%

Do analysts recommend MTVA or GNPX?

MetaVia presently has a consensus target price of $20.00, indicating a potential upside of 1,269.86%. Given MetaVia's stronger consensus rating and higher probable upside, equities analysts plainly believe MetaVia is more favorable than Genprex. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MetaVia 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Genprex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings and valuation, MTVA or GNPX?

MetaVia is trading at a lower price-to-earnings ratio than Genprex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MetaVia N/A N/A -$12.97M -$3.23 N/A Genprex N/A N/A -$16.23M -$133.36 N/A

Is MTVA or GNPX more profitable?

Genprex's return on equity of -163.12% beat MetaVia's return on equity. Company Net Margins Return on Equity Return on Assets MetaVia N/A -209.67% -107.91% Genprex N/A -163.12% -128.98%

Do analysts rate FBLG or GNPX?

FibroBiologics currently has a consensus price target of $73.00, suggesting a potential upside of 6,303.51%. Given FibroBiologics' stronger consensus rating and higher possible upside, analysts clearly believe FibroBiologics is more favorable than Genprex. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score FibroBiologics 2 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.80 Genprex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation and earnings, FBLG or GNPX?

FibroBiologics is trading at a lower price-to-earnings ratio than Genprex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio FibroBiologics N/A N/A -$18.65M -$5.19 N/A Genprex N/A N/A -$16.23M -$133.36 N/A

Is FBLG or GNPX more profitable?

Genprex's return on equity of -163.12% beat FibroBiologics' return on equity. Company Net Margins Return on Equity Return on Assets FibroBiologics N/A -536.78% -225.12% Genprex N/A -163.12% -128.98%

Do analysts rate XCUR or GNPX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Exicure 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Genprex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings & valuation, XCUR or GNPX?

Exicure has higher revenue and earnings than Genprex. Exicure is trading at a lower price-to-earnings ratio than Genprex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Exicure $500K 13.36 -$4.95M -$1.32 N/A Genprex N/A N/A -$16.23M -$133.36 N/A

Is XCUR or GNPX more profitable?

Genprex's return on equity of -163.12% beat Exicure's return on equity. Company Net Margins Return on Equity Return on Assets Exicure N/A -237.91% -61.98% Genprex N/A -163.12% -128.98%

Genprex (GNPX) Competitors

$2.69 +0.07 (+2.67%)

As of 10:34 AM Eastern

Compare

GNPX vs. LGVN, OSRH, MTVA, FBLG, and XCUR

Should you buy Genprex stock or one of its competitors? Genprex's main competitors and comparable companies include Longeveron (LGVN), OSR (OSRH), MetaVia (MTVA), FibroBiologics (FBLG), and Exicure (XCUR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Genprex compare to Longeveron?

Longeveron (NASDAQ:LGVN) and Genprex (NASDAQ:GNPX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, media sentiment, analyst recommendations, institutional ownership and profitability.

In the previous week, Longeveron had 3 more articles in the media than Genprex. MarketBeat recorded 3 mentions for Longeveron and 0 mentions for Genprex. Longeveron's average media sentiment score of 0.00 equaled Genprex'saverage media sentiment score.

Company	Overall Sentiment
Longeveron	Neutral
Genprex	Neutral

Genprex has a net margin of 0.00% compared to Longeveron's net margin of -1,977.59%. Genprex's return on equity of -163.12% beat Longeveron's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Longeveron	-1,977.59%	-223.19%	-150.20%
Genprex	N/A	-163.12%	-128.98%

Genprex has lower revenue, but higher earnings than Longeveron. Longeveron is trading at a lower price-to-earnings ratio than Genprex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Longeveron	$1.20M	6.49	-$22.70M	-$9.90	N/A
Genprex	N/A	N/A	-$16.23M	-$133.36	N/A

Longeveron currently has a consensus price target of $80.00, indicating a potential upside of 3,178.69%. Given Longeveron's stronger consensus rating and higher probable upside, analysts plainly believe Longeveron is more favorable than Genprex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Longeveron	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Genprex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

10.0% of Longeveron shares are held by institutional investors. Comparatively, 14.1% of Genprex shares are held by institutional investors. 7.4% of Longeveron shares are held by company insiders. Comparatively, 0.3% of Genprex shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Longeveron has a beta of -0.19, meaning that its share price is 119% less volatile than the broader market. Comparatively, Genprex has a beta of -0.99, meaning that its share price is 199% less volatile than the broader market.

Summary

Longeveron beats Genprex on 8 of the 14 factors compared between the two stocks.

How does Genprex compare to OSR?

Genprex (NASDAQ:GNPX) and OSR (NASDAQ:OSRH) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, profitability, valuation, media sentiment, dividends and risk.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genprex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
OSR	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Genprex's average media sentiment score of 0.00 equaled OSR'saverage media sentiment score.

Company	Overall Sentiment
Genprex	Neutral
OSR	Neutral

Genprex has a net margin of 0.00% compared to OSR's net margin of -593.15%. OSR's return on equity of -8.36% beat Genprex's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genprex	N/A	-163.12%	-128.98%
OSR	-593.15%	-8.36%	-6.24%

Genprex has a beta of -0.99, meaning that its share price is 199% less volatile than the broader market. Comparatively, OSR has a beta of 0.48, meaning that its share price is 52% less volatile than the broader market.

14.1% of Genprex shares are owned by institutional investors. Comparatively, 55.3% of OSR shares are owned by institutional investors. 0.3% of Genprex shares are owned by insiders. Comparatively, 36.9% of OSR shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Genprex has higher earnings, but lower revenue than OSR. OSR is trading at a lower price-to-earnings ratio than Genprex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genprex	N/A	N/A	-$16.23M	-$133.36	N/A
OSR	$1.81M	4.17	-$27.06M	-$0.37	N/A

Summary

OSR beats Genprex on 7 of the 10 factors compared between the two stocks.

How does Genprex compare to MetaVia?

MetaVia (NASDAQ:MTVA) and Genprex (NASDAQ:GNPX) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends, earnings and media sentiment.

MetaVia has a beta of 0.96, indicating that its share price is 4% less volatile than the broader market. Comparatively, Genprex has a beta of -0.99, indicating that its share price is 199% less volatile than the broader market.

MetaVia is trading at a lower price-to-earnings ratio than Genprex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MetaVia	N/A	N/A	-$12.97M	-$3.23	N/A
Genprex	N/A	N/A	-$16.23M	-$133.36	N/A

1.4% of MetaVia shares are owned by institutional investors. Comparatively, 14.1% of Genprex shares are owned by institutional investors. 0.6% of MetaVia shares are owned by company insiders. Comparatively, 0.3% of Genprex shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, MetaVia had 1 more articles in the media than Genprex. MarketBeat recorded 1 mentions for MetaVia and 0 mentions for Genprex. MetaVia's average media sentiment score of 0.00 equaled Genprex'saverage media sentiment score.

Company	Overall Sentiment
MetaVia	Neutral
Genprex	Neutral

Genprex's return on equity of -163.12% beat MetaVia's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MetaVia	N/A	-209.67%	-107.91%
Genprex	N/A	-163.12%	-128.98%

MetaVia presently has a consensus target price of $20.00, indicating a potential upside of 1,269.86%. Given MetaVia's stronger consensus rating and higher probable upside, equities analysts plainly believe MetaVia is more favorable than Genprex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MetaVia	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Genprex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

MetaVia beats Genprex on 9 of the 12 factors compared between the two stocks.

How does Genprex compare to FibroBiologics?

FibroBiologics (NASDAQ:FBLG) and Genprex (NASDAQ:GNPX) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, risk, media sentiment, valuation, earnings, analyst recommendations, profitability and dividends.

14.1% of Genprex shares are owned by institutional investors. 7.3% of FibroBiologics shares are owned by insiders. Comparatively, 0.3% of Genprex shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

FibroBiologics currently has a consensus price target of $73.00, suggesting a potential upside of 6,303.51%. Given FibroBiologics' stronger consensus rating and higher possible upside, analysts clearly believe FibroBiologics is more favorable than Genprex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
FibroBiologics	2 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.80
Genprex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, FibroBiologics had 1 more articles in the media than Genprex. MarketBeat recorded 1 mentions for FibroBiologics and 0 mentions for Genprex. FibroBiologics' average media sentiment score of 0.32 beat Genprex's score of 0.00 indicating that FibroBiologics is being referred to more favorably in the media.

Company	Overall Sentiment
FibroBiologics	Neutral
Genprex	Neutral

Genprex's return on equity of -163.12% beat FibroBiologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
FibroBiologics	N/A	-536.78%	-225.12%
Genprex	N/A	-163.12%	-128.98%

FibroBiologics is trading at a lower price-to-earnings ratio than Genprex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
FibroBiologics	N/A	N/A	-$18.65M	-$5.19	N/A
Genprex	N/A	N/A	-$16.23M	-$133.36	N/A

FibroBiologics has a beta of 1.72, suggesting that its share price is 72% more volatile than the broader market. Comparatively, Genprex has a beta of -0.99, suggesting that its share price is 199% less volatile than the broader market.

Summary

FibroBiologics beats Genprex on 8 of the 13 factors compared between the two stocks.

How does Genprex compare to Exicure?

Exicure (NASDAQ:XCUR) and Genprex (NASDAQ:GNPX) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, risk, earnings, profitability, analyst recommendations, dividends, valuation and media sentiment.

Exicure has higher revenue and earnings than Genprex. Exicure is trading at a lower price-to-earnings ratio than Genprex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exicure	$500K	13.36	-$4.95M	-$1.32	N/A
Genprex	N/A	N/A	-$16.23M	-$133.36	N/A

Exicure has a beta of 3.64, suggesting that its stock price is 264% more volatile than the broader market. Comparatively, Genprex has a beta of -0.99, suggesting that its stock price is 199% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exicure	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Genprex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Exicure had 1 more articles in the media than Genprex. MarketBeat recorded 1 mentions for Exicure and 0 mentions for Genprex. Exicure's average media sentiment score of 0.00 equaled Genprex'saverage media sentiment score.

Company	Overall Sentiment
Exicure	Neutral
Genprex	Neutral

Genprex's return on equity of -163.12% beat Exicure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exicure	N/A	-237.91%	-61.98%
Genprex	N/A	-163.12%	-128.98%

42.8% of Exicure shares are owned by institutional investors. Comparatively, 14.1% of Genprex shares are owned by institutional investors. 52.8% of Exicure shares are owned by company insiders. Comparatively, 0.3% of Genprex shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Exicure beats Genprex on 8 of the 10 factors compared between the two stocks.

Get Genprex News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GNPX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GNPX vs. The Competition

Export

Metric	Genprex	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.20M	$3.81B	$7.12B	$13.32B
Dividend Yield	N/A	3.66%	2.53%	16.47%
P/E Ratio	-0.02	13.71	275.34	26.03
Price / Sales	N/A	1,189.72	575.56	85.81
Price / Cash	N/A	118.37	77.41	52.81
Price / Book	0.05	16.06	10.76	6.24
Net Income	-$16.23M	-$22.65M	$3.50B	$381.89M
7 Day Performance	5.08%	-3.67%	-1.99%	-1.29%
1 Month Performance	-24.01%	-12.91%	-7.52%	-5.52%
1 Year Performance	-99.00%	8.61%	2.87%	-1.47%

Genprex Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GNPX Genprex	0.2826 of 5 stars	$2.69 +2.7%	N/A	-98.8%	$2.20M	N/A	N/A	13	Gap Up
LGVN Longeveron	1.7032 of 5 stars	$2.59 -0.2%	$80.00 +2,994.8%	-69.8%	$8.25M	$1.20M	N/A	38
OSRH OSR	0.0834 of 5 stars	$0.23 -6.9%	N/A	-64.5%	$8.08M	$1.81M	N/A	N/A	Gap Down
MTVA MetaVia	2.2957 of 5 stars	$1.56 +1.3%	$20.00 +1,182.1%	-87.5%	$8.05M	N/A	N/A	8
FBLG FibroBiologics	2.0171 of 5 stars	$1.16 -4.1%	$73.00 +6,220.3%	-88.4%	$7.69M	N/A	N/A	15

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GNPX) was last updated on 10/8/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Genprex (GNPX) Competitors